alexa Abstract | Clinical Prognostic Models in Diffuse Large B Cell Lymphoma Patients are Still Essential in the Rituximab Era
ISSN: 2329-8790

Journal of Hematology & Thromboembolic Diseases
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access

Abstract

Introduction: To evaluate a new enhanced IPI proposal by the National Comprehensive Cancer Network (NCCNIPI) in DLBCL patients, we compared the IPI, R-IPI, and NCCN-IPI in DLBCL patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone (R-CHOP).

Methods: From June 2008 to January 2012, we retrospectively evaluated 146 DLBCL patients treated with RCHOP- 21 referred for cancer treatment in a single institution in Brazil. Patients' clinical data were assessed to calculate the IPI, R-IPI, and NCCN-IPI.

Results: Patients' median age was 58.9 years (range 16-86); 85 (57.8%) were female. According to IPI, risk categories were low (n=41, 28.1%), low-intermediate (n=43, 29.5%), high-intermediate (n=37, 25.3%), and high (n=25, 17.1%). Using R-IPI, risk categories were very good (n=19, 13%), good (n=65, 44.5%), and poor (n=62, 42.5%). According to NCCN-IPI, risk categories were low (n=12/147, 8.2%), low-intermediate (n=52/147, 35.6%), high-intermediate (n=62/147, 42.5%), and high (n=20/147, 13.7%). The median follow up was 42.8 months (0.6-71.2) with an overall survival (OS) at 48 months of 73.8% and 84.3% of PFS. Using IPI, the OS at was higher for low and low- intermediate risk than high and high-intermediate risk patients (85.9% vs. 59.2% p<0.001). The RIPI showed significant differences in OS (100% vs. 83.2% vs. 57.5% p<0.001) but not for PFS (p=0.67) among very good, good and poor risk groups. The NCCN-IPI demonstrated significant differences in OS (p<0.001) among lowintermediate, high-intermediate, and high-risk groups, with the high-risk group exhibiting worse OS (35% at 48 months) but not for PFS (0.166). According to IPI, the OS in high-intermediate and high-risk patients was 59.2%. Conclusion: In our study, the NCCN-IPI (but not the IPI or R-IPI) was able to discriminate a group of patients of higher risk of DLBCL treated with R-CHOP with worse median OS.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Costa RO, Neto AH, Siqueira S, Lage LAPC, Paula HM, et al.

Keywords

Diffuse large B-cell lymphoma, Rituximab, Polychemotherapy, Prognosis, Brazilian patients, B-cell Lymphoma, Immuoglobulins, Iron Therapy

Share This Page

Additional Info

Loading
Loading Please wait..
 
 
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords